Munich based health technology startup dehaze has secured €3.2 million in seed funding as it works to transform how chronic diseases are detected and managed. By developing a foundational artificial intelligence model tailored specifically for healthcare data, the company aims to shift diagnosis from reactive treatment to proactive prevention.
Investor Backing and Growth Strategy
The funding round was led by YZR Capital and DN Capital, with participation from Angel Invest, Zoho, and Better Ventures. The investment highlights growing confidence in AI driven healthcare solutions that focus on early detection and cost reduction.
The newly raised capital will be used to expand both the technical and commercial teams, while also advancing the platform’s capabilities. Planned enhancements include features that recommend next best actions for patient care and improve traceability in clinical decision making.
Tackling a Global Healthcare Challenge
Chronic diseases represent one of the largest challenges facing global healthcare systems. According to the World Health Organization, these conditions account for around 70 percent of deaths worldwide and generate more than $8 trillion in annual healthcare spending.
Despite the vast amount of medical data available, healthcare professionals often review only a small portion of it when making decisions. This limitation contributes to many conditions being detected at later stages, when treatment is more complex and less effective.
dehaze is addressing this gap by building technology that can process and analyse large scale patient data, enabling earlier identification of individuals at risk.
A Purpose Built AI Model
Unlike many healthcare AI solutions that rely on general purpose models or interface driven tools, dehaze is developing a system designed specifically for medical data. Its platform uses causal AI to analyse relationships within complex datasets, moving beyond simple pattern recognition to understand underlying factors that contribute to disease development.
This approach allows the system to generate insights that are directly actionable for healthcare providers and insurers. By identifying risk factors earlier, the platform supports more targeted interventions, improving patient outcomes while reducing overall costs.
Supporting Payers and Providers
dehaze’s technology is particularly relevant for healthcare payers, who are under increasing pressure to manage costs while improving care quality. By enabling earlier detection of chronic conditions, the platform can help reduce medical loss ratios and optimise resource allocation.
At the same time, clinicians benefit from more comprehensive insights, allowing them to make informed decisions based on a broader view of patient data. This combination of clinical and financial impact positions dehaze at the intersection of healthcare delivery and system efficiency.
Building a Global Platform
Co founder and CEO Marius Klages emphasised that the company was designed from the outset to address a global problem. Chronic diseases affect populations worldwide, and the need for scalable, data driven solutions is universal.
The company reports strong early traction, with healthcare payers showing increasing interest in adopting its platform. This demand reflects a broader shift toward preventive healthcare models that prioritise early intervention over reactive treatment.
Shaping the Future of Healthcare AI
As healthcare systems continue to generate vast amounts of data, the ability to extract meaningful insights will become increasingly critical. dehaze is positioning itself as a key player in this transformation by focusing on foundational AI models that can operate at scale.
With fresh funding and a clear focus on early disease detection, the company is taking steps to redefine how chronic conditions are identified and managed. By enabling faster, more accurate insights, dehaze aims to contribute to a future where healthcare is more proactive, efficient, and effective.
